X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-clinical-development-plan
https://endpts.com/aldeyra-braces-for-potential-dry-eye-disease-rejection-after-fda-says-more-data-is-necessary/
https://www.reuters.com/business/healthcare-pharmaceuticals/aldeyra-therapeutics-eye-treatment-meets-late-stage-study-main-goal-2023-06-15/
https://www.who.int/news/item/15-09-2022-who-responds-to-the-lancet-covid-19-commission
https://seekingalpha.com/article/4529549-aldeyra-therapeutics-poised-for-dry-eye-disease-therapy-monetization
https://www.fiercebiotech.com/biotech/after-late-study-endpoint-switch-aldeyra-hails-success-phase-3-dry-eye-disease-trial
https://endpts.com/aldeyra-shares-spiral-after-a-late-stage-failure-in-dry-eye-disease-but-that-wont-stop-its-pursuit-of-an-nda/
https://www.clinicaltrialsarena.com/news/aldeyra-enrolment-dry-eye-disease/
https://www.fiercebiotech.com/biotech/aldeyra-s-dry-eye-drug-helps-redness-but-misses-other-phase-2-goals-important-measures
https://www.businesswire.com/news/home/20201208005379/en/Aldeyra-Announces-First-Patient-Enrolled-in-the-Phase-3-TRANQUILITY-Trial-of-Reproxalap-for-the-Treatment-of-Dry-Eye-Disease
https://www.biospace.com/article/releases/aldeyra-to-present-new-reproxalap-data-from-phase-2-clinical-trial-in-allergic-conjunctivitis-at-american-academy-of-ophthalmology-2020-annual-meeting/
https://www.biospace.com/article/releases/aldeyra-therapeutics-announces-positive-top-line-results-from-part-1-of-adaptive-phase-3-renew-trial-in-dry-eye-disease/
https://endpts.com/aldeyras-eye-drug-stumbles-in-pivotal-test-in-patients-with-rare-inflammatory-disease/
https://www.fiercebiotech.com/biotech/aldeyra-s-anti-allergy-eyedrop-sails-through-first-phase-3-trial-boosting-stock-price-by
https://www.xconomy.com/national/2018/09/28/bio-roundup-amarins-stunner-lung-cancer-news-data-dumps-more/
https://www.biopharmadive.com/news/aldeyra-has-positive-dry-eye-data-for-now/533299/
Market Place
Share 
